Early Gestational Glucose Intolerance (EGGI): A Comprehensive Review of Current Evidence and Its Future Directions
Sanjev Dave 1*, Dr Nidhi Tiwari2
- Prof & HOD, Community Medicine, PSLMDABH ASMC Auraiya, (UP); 2. SR Community Medicine, UPUMS, Safai,
Etawah(UP)
*Corresponding Author: Prof & HOD, Community Medicine, PSLMDABH ASMC Auraiya, (UP);
[email protected]
Submitted: 20 June 2026; Accepted: 2 July 2026; Published: 20 July 2026
Background: Gestational diabetes mellitus (GDM) has traditionally been screened for and diagnosed between 24 and 28 weeks of gestation. Rising rates of obesity, insulin resistance, and first-trimester hyperglycemia — particularly in South Asian and Indian populations — have driven interest in earlier detection.
Objectives: Early Gestational Diabetes Mellitus (eGDM), typically diagnosed before 20–24 weeks using fasting plasma glucose thresholds, has been increasingly studied, most notably through the multicentre Treatment of Booking Gestational Diabetes Mellitus (TOBOGM) trial.
Methods: More recently, Indian investigators have proposed an even earlier construct — Early Gestational Glucose Intolerance (EGGI) — defined as a postprandial blood glucose (PPBG)≥110 mg/dl detected at 8–10 weeks of gestation, before fetal beta-cell insulin secretion begins around the 10th–11th week. Results: This review synthesizes the physiological rationale, proposed diagnostic criteria, available evidence (including the Diabetes in Pregnancy Study Group India [DIPSI] test, the TOBOGM trial, and Indian hospital-based EGGI cohorts), management strategies centered on Medical Nutrition Therapy (MNT) and metformin, and the current controversies and evidence gaps surrounding EGGI.
Conclusion: While early observational and interventional data suggest that identifying and treating EGGI may reduce composite adverse
neonatal outcomes, the concept remains outside mainstream international guidelines, and larger randomized trials are needed before EGGI can be recommended for universal, first-trimester screening.
